



Ampeptec

# Novel Insulin APT3598 from Ampeptec for Once-Weekly Injection



January 2025




The World's Leading Peptide Experts


# Novel Insulin APT3598 for Once-Weekly Injection

- **APT3598** has high potential for a **pharmacologically better once-weekly injection drug** as compared to Insulin Icodec.
- **APT3598** controls **glucose better than Novo Nordisk's Insulin Icodec** in Sprague-Dawley rats, **more consistently and for a longer time** as shown below in the graph where APT3598 was able to maintain Glucose level **uniformly** for 48 hours as compared to Insulin Icodec .
- **Insulin Icodec** was recently approved as once a weekly injection in EU and China **but not in the USA due to hypoglycemia risks**. APT3598 does not drop Glucose level as low as Icodec as shown below demonstrating lower Hypoglycemic risks than Icodec.
- The **global 2023 sales** of commercially approved once-daily insulin Degludec and insulin Glargine were **\$815 million and >\$ 2 billion**, respectively. The global insulin market is **>\$40 billion and still growing** with the increasing diabetes population.

In Sprague-Dawley rats, 175 nmol/rat APT3598 lowers glucose levels by ~50% within 48 hours, which is better compared to 175 nmol/rat Degludec and Icodec.



**Intellectual Property** : U.S. Patent Application No. 18/945.043 and PCT patent application No. PCT/IB2024/061252: "INSULIN ANALOGS FOR THE TREATMENT OF HUMAN METABOLIC DISORDERS AND DISEASE"



Contact: Rob Camerer  
[RobCamerer@globalpharmapartners.com](mailto:RobCamerer@globalpharmapartners.com)

T. Kjeldsen et al. Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans. J. Med. Chem. 2021, 64, 8942–8950

Notes: Icodec 100 & 200 Copied from T. Kjeldsen et al. published data